BySiladitya Ray,
Forbes Staff.
Shares of Novo Nordisk slumped to their lowest level since July 2021 on Monday morning after the drugmaker announced that its long-shot trial testing the impact of its Ozempic on the progression of Alzheimer’s disease failed to meet its key goal.
Novo Nordisk’s Copenhagen shares fell by more than 12%, before recovering slightly to Kr 273.35 ($42.25), down around 10.3%.
In a press release, the company said its pair of large trials covering 3,808 adults examining the impact of semaglutide—the active ingredient in the company’s weight-loss drug Ozempic—on the progression of Alzheimer’s failed to meet their primary goal.
